Cervical And Self-Sample In Screening Study
キーワード
概要
説明
After the discovery that Human Papillomavirus (HPV) infection is the necessary cause of cervical cancer there have been much interest in the introduction of novel screening strategies involving HPV DNA testing [1]. HPV DNA testing was shown to have higher sensitivity in detecting cervical cancer and its precursors and greater reproducibility than Papanicolaou (Pap) cytology screening and has been therefore proposed as the primary screening method for the future. In high-income countries, cases of cervical cancer continue to develop among unscreened and under-screened women [2]. Factors discouraging women from attending routine screening include fear of pain or discomfort, lack of time or perceived inconvenience, cultural or religious concerns, and poor socioeconomic status [3]. For a screening program to be effective high coverage is essential and thus attendance is a critical requirement.
Because of the high sensitivity of molecular HPV testing to detect cervical cancer precursors there is great potential for screening coverage to be increased by inviting non-attendant to provide self-collected vaginal samples. Providing these women with a simple, convenient, and inexpensive means of self-testing may improve cervical screening participation [3]. Self-sampling is also an attractive approach to assist screening in poor countries, which typically do not have structured cervical cancer screening programs while having to bear the greatest burden of cervical cancer morbidity and mortality [4]. Self-sampling can also enhance the value of post-HPV vaccination surveillance by allowing a more efficient monitoring of HPV type distribution in populations. Finally, self-sampling represents a good research tool to assist prospective studies of genital HPV infection and natural history of cervical neoplasia.
Specifically for cervical cancer screening, it has been shown that self-collected cervicovaginal specimens from women who received proper instruction for collecting them yield HPV test results that are comparable to those in specimens collected by physicians [5-8]. Women also prefer self-sampling relative to clinician-provided samples, provided that they can be assured that they are told how to properly collect the sample [8, 9]. Although there is conceivably some loss of sensitivity and specificity in screening for cervical cancer in a specimen that is not directly collected from the ecto- and endo-cervix the overall accuracy of the HPV testing results (to identify presence of cervical precancerous lesions) is still superior to that of physician-collected Pap smears. Therefore, replacing a more anatomically-correct specimen (the one collected with direct visualization of the cervix by a primary healthcare provider) with one collected from the vagina (and thus diluted with exfoliated cells from a wider epithelial surface area) is compensated by the high sensitivity of the molecular screening approach [6, 10, 11]. Performance of screening seems also to be unaffected by storage and transport of the self-sample swabs, irrespective of whether they have been kept dry or transferred and resuspended into a liquid transport medium [10, 12].
A critical feature in enhancing women's acceptance and adherence with the self-sampling approach for cervical cancer screening and HPV surveillance studies is the convenience of the device used for collection. Dacron and polyester swabs are simple, common, and inexpensive. However, they are inconvenient and not isolated within a sheath that prevents contact of the sampling area with mucosal surfaces in the labia and vaginal opening. Ideally, sampling devices should be anatomically correct to facilitate insertion and the sampling surface that will retain the exfoliated cells should be protected from contact with the labia and lower vaginal mucosa while the device is inserted, with the objective of sampling cells that are mostly from the cervix and upper vaginal area.
HPV DNA testing using self-collected cervicovaginal specimens represents a promising strategy to increase cervical screening participation and thus reduce rates of cervical cancer in countries with established cervical screening programs. Furthermore, this approach can also greatly improve the coverage and quality of cervical cancer screening in developing countries, as well as in remote regions in developed countries, e.g., aboriginal populations in Northern Quebec and in First Nations territories. Facilitating and improving uptake of cervical cancer screening would save lives, reduce costs of treating invasive cancer and potentially reduce inequalities in avoidable mortality caused from cervical cancer.
(full protocol available upon request)
日付
最終確認済み: | 07/31/2016 |
最初に提出された: | 02/23/2015 |
提出された推定登録数: | 03/17/2015 |
最初の投稿: | 03/23/2015 |
最終更新が送信されました: | 08/15/2016 |
最終更新日: | 08/16/2016 |
実際の研究開始日: | 05/31/2015 |
一次完了予定日: | 03/31/2016 |
研究完了予定日: | 03/31/2016 |
状態または病気
介入/治療
Device: Eve Medical self-collection system©
Device: cobas® PCR Female swab self-sampling
Procedure: Physician-collected sampling
段階
アームグループ
腕 | 介入/治療 |
---|---|
Experimental: Eve Medical self-collection system© Device: Self-sampling swab from Eve Medical for collection of vaginal cells. | Device: Eve Medical self-collection system© The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening. |
Placebo Comparator: cobas® PCR Female swab self-sampling Device: Regular polyester swab for collection of vaginal cells. | Device: cobas® PCR Female swab self-sampling Regular polyester swab for collection of vaginal cells. |
Placebo Comparator: Physician-collected sampling Routine colposcopy sample collected by a physician. | Procedure: Physician-collected sampling Routine colposcopy sample collected by a physician. |
適格基準
研究に適格な性別 | Female |
健康なボランティアを受け入れる | はい |
基準 | Inclusion Criteria: - Women of all ages are eligible to the study if they have been referred to the participating colposcopy clinic because of an abnormal Pap test at the level of an atypical squamous cells of undetermined significance or worse squamous or glandular abnormality (i.e., ASCUS+) or an abnormal co-test (ASCUS+ and HPV-positive) result. Exclusion Criteria: - none |
結果
主な結果の測定
1. Differences by comparison groups in detection of histologically confirmed Cervical Intraepithelial Neoplasia grade 1 or worse (CIN1+) [Cross-Sectional (1 year-period to accrue patients)]
二次的な結果の測定
1. Patient satisfaction and experience using the self-sampling devices [Cross-Sectional (1 year-period)]